prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype Normal, Clinical Diagnosis & History: Biopsy proven left breast ILC, approximately 3-4 cm in si-e. Presents for. left TM, SLN Biopsy, as well as right TM. Protocol. History of right. breast MRI guided core biopsy. Specimens Submitted: 1: SP: Sentinel node #1 level one left axilla (fs). 2: SP: Sentinel node #2 level one left axilla (fs). 3: SP: Sentinel node #3 level one left axilla (Es). 4: SP: Right breast. 5: SP: Left breast. 6 : SP: Additional lympn node, left axilla. DIAGNOSIS: SENTINEL LYMPH NODE #1, LEVEL I LEFT AXILLA, EXCISION: - ONE BENIGN LYMPH NODE (0/1). - ADDITIONAL H/E STAINED SECTIONS AND IMMMUNOPEROXIDASE STAINS FOR. CITOKERATINS (AE1:AE3) SHOW NO EVIDENCE OF METASTATIC CARCINOMA. SENTINEL LYMPH NODE #2, LEVEL I LEFT AXILLA, EXCISION: ONE BENIGN LYMPH NODE (0/1). - ADDITIONAL H/E STAINED SECTIONS AND IMMUNOPEROXIDASE STAINS FOR. CITOKERATINS (AE1:AE3) SHOW NO EVIDENCE OF METASTATIC CARCINOMA. 3). SENTINEL LYMPH NODE #3, LEVEL I LEFT AXILLA, EXCISION: - METASTATIC CARCINOMA IN THE FORM OF MICROSCOPIC CLUSTERS AND SINGLE. CELLS IS IDENTIFIED IN ONE OF ONE LYMPH NODE ON ADDITIONAL CYTOKERATINS. IMMUNOHISTOCHEMICAL STAINS (AE1:AE3) EACH CLUSTER OF CARCINOMA MEASURES. LESS THAN 0.2 MM, BUT SEVERAL CLUSTERS ARE PRESENT DISPERSED THROUGHOUT THE. LYMPH NODE, ADDING UP TO ABOUT 300-400 CELLS IN TOTAL. RARE TUMOR CLUSTERS ARE ALSO IDENTIFIED ON ADDITIONAL H/E STAINED SECTIONS. 4). BREAST, RIGHT TOTAL NASTECTONY: - BENIGN BREAST TISSUE WITH FOCAL ATYPICAL DUCTAL HYPERPLASIA (ADH),. COLUMNAR CELLS,. FIBROADENOMATOID CHANGES AND BIOPSY SITE. - CALCIFICATIONS ARE ASSOCIATED WITH ADH AND BENIGN EPITHELIUM. - BENIGN SKIN AND NIPPLE. 5). BREAST, LEFT, TOTAL MASTECTOMY: :riteria. - INVASIVE LOBULAR CARCINOMA. CLASSICAL TYPE, PRESENT AS MULTIPLE FOCI. DISTRIBUTED OVER AN AREA SPANNING ABOUT 6 CM GROSSLY. - EXTENSIVE LOBULAR CARCINOMA IN SITU (LCIS) IS ALSO IDENTIFIED,. CLASSICAL TYPE (TYPE A). - THE INVASIVE CARCINOMA IS LOCATED IN THE UPPER OUTER QUADRANT AND. LOWER OUTER QUADRANT. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINONA. IS IDENTIFIED. - CALCIFICATIONS ARE PRESENT IN THE IN SITU AND INVASIVE CARCINOMA, AND. IN BENIGN BREAST. PARENCHYMA. - NO VASCULAR INVASION IS NOTED. - NO PERINEURAL INVASION IS IDENTIFIED IN A SECTION IMMUNOSTAINED FOR. CYTOKERATIN AE1:AE3. - INVASIVE CARCINOMA IS 0.6 CM FROM THE NEAREST (DEEP) MARGIN. - NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. THE SKIN SHONS SCAR. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE, FIBROADENOMATOID. CHANGES AND APOCRINE METAPLASIA. IMMUNOHISTOCHEMICAL STAINS WERE PERFORMED ON FORMALIN-FIKED TISSUE WITH. THE FOLLOWING RESULTS FOR INVASIVE CARCINOMA (BLOCK 5-5) : ESTROGEN RECEPTOR (6F11, VENTANA) : 95% NUCLEAR STAINING WITH STRONG. INTENSITY. PROGESTERONE RECEPTOR (1E2; VENTANA) : 90% NUCLEAR STAINING WITH STRONG. INTENSITY. HER2 (HERCEPTEST: DAKO) : NEGATIVE (0). CONTROLS ARE SATISFACTORY. Comment: HercepTestTM (Dako) is an YDA-approved method for assessment of. HER2 protein overexpression in breast cancer tissue routinely processed for. histological evaluation. The HER2 test results are reported in accordance. with the ASCO/CAP guideline recommandations for HER2 testing in breast. cancer (J Clin Oncol 2007; 25 (1):118-145) Some of the immmunohistochemimtry. and ISH tests were developad and their performance characteristics were. determined by the Department of Pathology. They have not been cleared or. approved by the us Food and Drug Administration. The FDA has determined that. such clearance or approval is not necessary. These tests are used for. clinical purposes. They should not be regarded as investigational or for. research. This laboratory is certified under the Clinical Laboratory. Improvement Amendments of 1988 (CLIA - 88) as qualified to perform high. complexity clinical laboratory testing. 6). LYMPH NODE, LEFT AXILLA, EXCISION: - ONE BENIGN LYMPH NODE (0/1). I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. 1). The specimen is received fresh for frozen section consultation, labeled. "sentinel node #1, level 1, left axilla" and consists of a pink tan firm. lymph node measuring 1.8 x 0.6 x 0.4 cm. The specimen is bisected and. entirely submitted for frozen section. Summary of sections: FSC -- frozen section control. 2) The specimen is received fresh for frozen section consultation, labeled. "sentinel node #2, level 1, left axilla" and consists of a pink tan firm. lymph node measuring 2.8 x 1.5 x 0.4 cm. The specimen is bisected and. entirely submitted for frozen section. Summary of sections: FSC -- frozen section control. 3). The specimen is received fresh for frozen section consultation, labeled. "sentinel node #3, level 1, left axilla" and consists of two pink tan firm. lymph nodes measuring 1.2 x 1.2 x 0.6 cm and 0.8 x 0.8 x 0.4 cm. The. specimen is bisected and entirely submitted for frozen section. Summary of sections: FSC frozen section control. 4). The specimen is received fresh labeled, "Right breast stitch marks. axillary tail" and consists of a breast measuring 19 x 18 x 3.5 cm with. overlying skin ellipse measuring 9.5 x 3.5 cm. Situated centrally on the. skin surface is an everted nipple measuring 1.7 x 1.5 x 0.3 cm and areola. measuring 3.7 x 3.4 cm. No visible scar is identified on the skin surface. A suture demarcates the axillary aspect. The posterior surface of the. breast is inked black, the anterior surface in inked blue and the specimen. is serially sectioned to reveal a dark red well circumscribed biopsy cavity. filled with red hemorrhagic material measuring 2.5 x 2 x 2 cm, and located. in the midline of the lower quadrants and 0.6 cm from the deep margin. A. clip is not identified in the specimen. Sectioning of the axillary aspect. reveals no grossly identifiable lymph nodes. Representative sections are. submitted. Sample of all quadrants were given to TPS protocol. Summary of sections: N nipple. NB - nipple base. S - skin scar. D - deep margin. BX - biopsy site. 3. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. 5). The specimen is received fresh labeled, "left breast and consists of. a. breast measuring 23 x 19 x 2 cm with overlying skin ellipse measuring 9 x 4. cm. Situated center on the skin surface is a nipple measuring 1.5 x 1.2. cm. and areola measuring 3.2 x 3.2 cm. The skin shows a linear scar measuring. 3. cm, situated lateral to the nipple. A suture demarcates the axillary. aspect. The posterior surface of the breast is inked black, the anterior. blue and the axillary aspect is inked yellow. The specimen is serially. sectioned to reveal a tan white firm stellate tumor mass measuring 6 x 3.5. x. 2.0 cm, located in LOQ 0.5 cm from the deep margin, extending to the. overlying skin. A clip is not identified. Sectioning of the axillary. aspect reveals no grossly identifiable lymph nodes. Representative sections. are submitted. Summary of sections: N - nipple. NB - nipple base. S - skin scar. D - deep margin. BX - biopsy site. T tumor. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. 6) The specimen is received in formalin, labeled 'additional lymph nodes. left axilla' and consists of irregular yellow tan lobulated tissue measuring. 0.8 x 0.3 x 0.3 cm. The specimen is entirely submitted. Summary of sections: LN- lymph nodes. Summary of Sections: Part 1: SP: Sentinel node #1 level one left axilla (fa). Block. Sect. Site. PCs. 1. FSC. 1. Part 2: SP: Sentinel node #2 level one left axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 3: SP: Sentinel node #3 level one left axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 4: SP: Right breast. Block. Sect. Site. PCs. 4. BX. 4. 1. D. 1. 2. LIQ. 2. 2. LOQ. 2. 1. N. 1. NB. 1. 1. S. 1. 2. UIQ. 2. 2. vog. 2. Part S: SP: Left breast. Block. Sect. Site. PCs. 2. 2. 1. BX. 1. 2. D. 2. 2. LIQ. 2. 2. LOQ. 2. 1. N. 1. NB. 1. 1. S. 1. 5. T. 5. 2. vog. 2. Part 6: SP: Additional lymph node, left axilla ,. Block. Sect. Site. PCs. 1. LN. 1. Procedures/Addenda: Addendunn. wace. Addendum Diagnosia. ADDENDUM. PART #5. LEFT BREAST: INVASIVE LOBULAR CARCINOMA IS PRESENT IN TEN OUT OF NINETEEN SLIDES, and. involves upper outer and lower outer quadrants. A microscopic focus of. invasive lobular carcinoma is also presaent in a section from the lower. inner quadrant (<lmm) THE SIZE OF THE INVASIVE TUMOR IS DIFFICULT TO. ASSESS IN THIS CASE, AS INVASIVE CARCINOMA IS PRESENT AS MULTIPLE NODULES,. MANY OF WHICH MERGE INTO ONE ANOTHER. THE LARGEST CONTIGUOUS SPAN OF. INVASIVE CARCINOMA MEASURES AT LEAST 2.0 CM MICROSCOPICALLY IN SLIDE 5-10. IN THIS SLIDE THE TUMOR IS PERIPHERALLY TRANSECTED ALONG A BROAD FRONT. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left axilla. (fa) (. : Benign. PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION TAGNOSIS: SP: Sentinel node #2 level one left axilla. : Benign. PERNANIENT DIAGNOSIS: SANE. 3). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #3 level one left axilla. (fs). Benign. PERMANENT DIAGNOSIS: SEE FINAL. Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left axilla. : Benign. PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #2 level one left axilla. Benign. PERMANENT DIAGI. SAME. 3). FROZEN SECTIOM PYAGNCSIS: SP: Sentinel node #3 level one left axilla. (fs). Benign. MANENT DIAGNOSIS: SEE FINAL.

expanded version (tokens=3448) : 
 The breast pathology report includes information on several specimens submitted for analysis. The following are the main points obtained from the report:

1. Subtype: Invasive lobular carcinoma (ILC), classical type, presenting as multiple foci. Extensive lobular carcinoma in situ (LCIS) is also identified, classical type A.
2. Histological grade/Nuclear grade: Not stated in the report.
3. Necrosis: No mention of necrosis in the report.
4. Tumor infiltrating lymphocytes: No information provided on tumor infiltrating lymphocytes.
5. Lymphovascular invasion: No evidence of lymphovascular invasion noted in the report.
6. Calcification: Calcifications are present in the in situ and invasive carcinoma and benign breast parenchyma.
7. Receptor status: Estrogen receptor (ER) staining shows 95% nuclear staining with strong intensity. Progesterone receptor (PR) staining shows 90% nuclear staining with strong intensity. HER2 (human epidermal growth factor receptor 2) is negative (0).
8. IHC: Additional IHC testing was performed on cytokeratins (AE1:AE3). 
9. Ancillary testing results: The HER2 test results are reported in accordance with the ASCO/CAP guideline recommendations for HER2 testing in breast cancer. Some of the immunohistochemistry and ISH tests were developed and their performance characteristics were determined by the Department of Pathology.



prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=3613) : 
 Report: 

Invasive lobular carcinoma (ILC) of classical type is identified in the left breast approximately 3-4 cm in size, presenting as multiple foci and extending to overlying skin. Extensive LCIS is also identified. ER and PR are positive, and HER2 is negative. No necrosis or lymphovascular invasion seen. Calcifications present in in situ, invasive carcinoma, and benign parenchyma. No information given on histological grade/nuclear grade or tumor infiltrating lymphocytes. Simple axillary dissection is recommended for management purposes.

